Short Interest in Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Expands By 453.3%

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) was the target of a significant increase in short interest in June. As of June 30th, there was short interest totaling 938,810 shares, an increase of 453.3% from the June 15th total of 169,677 shares. Currently, 4.2% of the company’s shares are short sold. Based on an average daily trading volume, of 5,496,954 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Jupiter Neurosciences Stock Down 4.3%

Jupiter Neurosciences stock traded down $0.01 during mid-day trading on Monday, hitting $0.18. The company’s stock had a trading volume of 598,549 shares, compared to its average volume of 3,564,877. Jupiter Neurosciences has a twelve month low of $0.17 and a twelve month high of $3.33. The stock has a market capitalization of $6.59 million, a P/E ratio of -0.67 and a beta of 1.73. The stock’s fifty day moving average price is $0.26 and its two-hundred day moving average price is $0.49.

Jupiter Neurosciences (NASDAQ:JUNS) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.23 million.

Institutional Trading of Jupiter Neurosciences

Hedge funds have recently modified their holdings of the stock. Allen Capital Group LLC acquired a new position in Jupiter Neurosciences during the fourth quarter worth $31,000. Yorkville Advisors Global LP bought a new stake in Jupiter Neurosciences in the fourth quarter valued at approximately $135,000. Geode Capital Management LLC boosted its position in Jupiter Neurosciences by 27.8% during the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after purchasing an additional 28,826 shares during the period. Finally, Vestor Capital LLC grew its stake in Jupiter Neurosciences by 144,607.2% in the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after buying an additional 970,314 shares during the last quarter.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.